Gujarat Themis Biosyn discloses indirect pledge over 47% of its shares

What Gujarat Themis Biosyn announced

Gujarat Themis Biosyn Ltd (ticker THEMISMED on NSE, 506879 on BSE) filed a Regulation 31 disclosure with the stock exchanges on 3 July 2026. The filing informs that an indirect encumbrance has been created over the shares of the company held by its promoter, Pharmaceutical Business Group (India) Limited (PBGIL). The encumbrance arises from a pledge and a non‑disposal undertaking executed by Vividhmargi Investments Private Limited (VIPL) in favour of CTL Trusteeship Limited, the debenture trustee.

"The creation of a pledge over 25,24,245 equity shares and a non‑disposal undertaking over 21,57,855 equity shares of PBGIL results in an indirect encumbrance over 5,12,40,000 equity shares of Gujarat Themis Biosyn held by PBGIL."

Details of the pledge and non‑disposal undertaking

• Pledge: 2,524,245 shares of PBGIL, representing 51 % of PBGIL’s issued and paid‑up capital, were pledged on 29 June 2026.
• Non‑disposal undertaking: 2,157,855 shares of PBGIL, representing 47.98 % of PBGIL’s capital, were subject to a non‑disposal undertaking on the same date.
• Beneficiary: Both instruments are in favour of CTL Trusteeship Limited, acting as the debenture trustee under a Debenture Trust Deed dated 25 June 2026.
• Purpose: The pledge and undertaking were executed pursuant to a Pledge Agreement‑cum‑Non‑Disposal Undertaking dated 28 June 2026, linked to the issuance of debentures by the promoter group.

Indirect encumbrance on Gujarat Themis Biosyn shares

PBGIL itself holds 5,12,40,000 equity shares of Gujarat Themis Biosyn, which equals 47.02 % of the target’s total equity. Because the pledge and non‑disposal undertaking are on PBGIL’s own shares, the effect is an indirect encumbrance on the entire stake that PBGIL holds in Gujarat Themis Biosyn. In practical terms, nearly half of Gujarat Themis Biosyn’s share capital is now subject to the trustee’s control for the purposes of the underlying debenture arrangement.

Key facts at a glance

Why this matters for investors

The filing does not alter the number of shares outstanding, but it does place a substantial portion of the promoter’s stake under a trustee’s control. The indirect encumbrance means that any future sale, transfer, or pledge of the 47.02 % promoter holding would require the consent of CTL Trusteeship Limited. This can affect the promoter’s flexibility in managing its equity position, especially in scenarios such as capital raising, restructuring, or a change of control. However, the filing does not indicate any immediate change to voting rights or dividend entitlement for the encumbered shares.

Conclusion

Gujarat Themis Biosyn has formally disclosed that almost half of its equity, held by promoter PBGIL, is now indirectly pledged and subject to a non‑disposal undertaking. The encumbrance is linked to a debenture arrangement and is held by CTL Trusteeship Limited. While the shares remain issued and outstanding, the promoter’s ability to dispose of or further pledge these shares is restricted until the underlying obligations are satisfied or the trustee releases the encumbrance.